Axel Grothey, MD, West Cancer Center & Research Institute
Advertisement
Articles by Axel Grothey, MD, West Cancer Center & Research Institute
Advertisement
Latest Updated Articles
Role of I/O Combination Therapies in mCRCPublished: June 29th 2020 | Updated:
Later Lines of Therapy for mCRCPublished: June 29th 2020 | Updated:
Therapeutic Agents in Relapsed/Refractory mCRCPublished: June 29th 2020 | Updated:
Using I/O in MSI-H Tumors in mCRCPublished: June 29th 2020 | Updated:
Key Trials in mCRC: I/O Combination TherapiesPublished: June 29th 2020 | Updated:
Second-Line Treatment for mCRCPublished: June 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5